Leishmaniasis is a debilitating disease prevalent across many inter-tropical regions of the world. Caused by over twenty species of parasite from the genus Leishmania and found in some species of sandflies, this disease can present itself in a number of different clinical manifestations including cutaneous, mucosal and visceral forms of the disease. Both the cutaneous and mucosal forms can cause severe disfigurements to patients including ulcerative skin lesions and the destruction of the mucous membranes of the nose, mouth and throat, leading to permanent disfigurement and frequent social ostracizing. Visceral forms can be more severe, with life-threatening symptoms such as fever, weight loss, and in some cases, enlargement of the liver and spleen. A shortfall of affordable and clinically effective treatments has led the World Health Organization to designate leishmaniasis as a Category 1 disease, signifying that it is an emerging and uncontrolled global health problem. Another infectious disease is Human African trypanosmiasis or sleeping sickness, a parasitic disease of people and animals caused by protozoa of the species Trypanosoma brucei, transmitted by the tsetse fly. Symptoms of this disease occur in two stages: the first causes fever and joint pain, and the second stage confusion, tremors, muscle weakness, and even partial paralysis. It is estimated that 50,000 to 70,000 people are currently infected. The current standard treatment for first stage trypanosomiasis employs an administration of intravenous pentamidine (for Trypanosoma brucei gambiense) or intravenous suramin (for Trypanosoma brucei rhodesiense). Treatment for the second stage of this disease is nifurtimoz and eflornithine (for Trypanosoma brucei gambiense) and melarsopol (for Tryponosoma brucei rhodesiense). Melarsopol is problematic such that drug resistance can occur and death is a possible side effect.